Cargando…

From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes

Detalles Bibliográficos
Autor principal:	Saygin, Caner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316268/ https://www.ncbi.nlm.nih.gov/pubmed/36794505 http://dx.doi.org/10.3324/haematol.2022.282477

Ejemplares similares

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia
por: Karantanos, Theodoros, et al.
Publicado: (2022)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Molecular Basis for CCRL2 Regulation of Leukocyte Migration
por: Schioppa, Tiziana, et al.
Publicado: (2020)

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome
por: Li, Xiao, et al.
Publicado: (2021)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
por: Zhao, Guangjie, et al.
Publicado: (2021)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes
por: Liu, Liu, et al.
Publicado: (2021)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
por: Liu, Xiaozhen, et al.
Publicado: (2023)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells
por: Reyes, Niradiz, et al.
Publicado: (2019)

CCRL2 Modulates Physiological and Pathological Angiogenesis During Retinal Development
por: Ben Dhaou, Cyrine, et al.
Publicado: (2021)

Exploring CCRL2 chemerin binding using accelerated molecular dynamics
por: Bufano, Marianna, et al.
Publicado: (2022)

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
por: Siamoglou, Stavroula, et al.
Publicado: (2023)

Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses In Vivo
por: Regan-Komito, Daniel, et al.
Publicado: (2017)

OsCCRL1 is Essential for Phenylpropanoid Metabolism in Rice Anthers
por: Zhang, Lisha, et al.
Publicado: (2023)

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
por: Stomper, Julia, et al.
Publicado: (2021)

ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling
por: Zhao, Guangjie, et al.
Publicado: (2022)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qj3fh3td4l38h8r5j1rmlpf1lk